Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evommune (EVMN) EBIT Margin (2024 - 2025)

Evommune (EVMN) has disclosed EBIT Margin for 2 consecutive years, with 133.28% as the latest value for Q3 2025.

  • Quarterly EBIT Margin fell 9729210.0% to 133.28% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 811.53% through Dec 2025, changed N/A year-over-year, with the annual reading at 623.62% for FY2025, 37656.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 133.28% at Evommune, down from 97158.82% in the prior quarter.
  • The five-year high for EBIT Margin was 97158.82% in Q3 2024, with the low at 133.28% in Q3 2025.